Alnylam is pleased to announce Promising Results from the ENVISION Phase III Study on Givosiran, an RNAi-Investigational Drug for the Treatment of acute hepatic Porphyria-MedSci.cn

Alnylam is pleased to announce Promising Results from the ENVISION Phase III Study on Givosiran, an RNAi-Investigational Drug for the Treatment of acute hepatic Porphyria

[Anonymous]

VISCERAL MEDICINE, 2019; 35 (4): 279

科室
- - 订阅+
  - 更多科室
工具
服务